Advancing RNA

2 weeks ago | advancingrna.com | Anna Welch |Advancing RNA |Erin Harris

Is The mRNA Payload The Real MVP Of Targeted Delivery? As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery.

Jan 13, 2025 | advancingrna.com | Anna Welch |Advancing RNA

By Anna Rose Welch, Editorial & Community Director, Advancing RNA At the end of every year, I sit down with several mRNA/RNA C-suite executives to take stock of the previous year and to discuss predictions for what is yet to come. For those of you who have been following my columns, you’ll know that this year’s interviews turned into a two-part Q&A series that channeled a few ghosts — the Charles Dickens ghosts of mRNA’s past/present and the ghosts of mRNA’s future, to be specific.

Jan 8, 2025 | advancingrna.com | AR Welch |Advancing RNA |Kishore Kumar Hotha |Antony Hitchcock

Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva.

Dec 11, 2024 | advancingrna.com | AR Welch |Advancing RNA |Tyler Menichiello |C. Schoellhammer

Customized mRNA-LNP SolutionsWith a combined 20-year track record in the manufacturing of lipids, LNP, and mRNA, MilliporeSigma offers customizable mRNA-LNP CDMO services to meet your unique needs from pre-clinical to commercialization. Select integrated services from drug substance to Fill & Finish or individual components tailored to your project. Download the infographic to learn more!During our hour-long conversation, Sagaert and I covered a lot of ground on the current state of the industry.

Nov 26, 2024 | advancingrna.com | Anna Welch |Advancing RNA

By Anna Rose Welch, Editorial & Community Director, Advancing RNA Over the past few months, I’ve been publishing articles centered on a topic that certainly seems miles and miles down the road for the RNA therapeutics space: Commercialization. However, having spent a few years in the biosimilar space, as well as the cell & gene therapy space prior to the mRNA world, I’ve become increasingly sensitive to the ways history tends to repeat itself across modalities.